Literature DB >> 22233579

Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.

Boris Engels1, Adam S Chervin, Andrea J Sant, David M Kranz, Hans Schreiber.   

Abstract

Most T cells have T cell receptors (TCR) of micromolar affinity for peptide-major histocompatibility complex (MHC) ligands, but genetic engineering can generate TCRs of nanomolar affinity. The affinity of the TCR used, m33, for its cognate non-self peptide-MHC-I complex (SIYRYYGL-K(b)) is 1,000-fold higher than of the wild-type TCR 2C. The affinity of m33 for the self-peptide dEV-8 on K(b) is only twofold higher. Mouse CD8(+) T cells transduced with an m33-encoding retrovirus showed binding of SIY-K(b) and potent function in vitro, but in vivo these T cells disappeared within hours after transfer into syngeneic hosts without causing graft-versus-host disease (GVHD). Accordingly, in cases where such CD8-dependent self-reactivity might occur in human adoptive T cell therapies, our results show that a peripheral T-cell deletion mechanism could operate to avoid reactions with the host. In contrast to CD8(+) T cells, we show that CD4(+) T cells expressing m33 survived for months in vivo. Furthermore, the m33-transduced CD4(+) T cells were able to mediate antigen-specific rejection of 6-day-old tumors. Together, we show that CD8(+) T cell expressing a MHC class I-restricted high-affinity TCR were rapidly deleted whereas CD4(+) T cells expressing the same TCR survived and provided function while being directed against a class I-restricted antigen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233579      PMCID: PMC3293607          DOI: 10.1038/mt.2011.286

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response.

Authors:  Y Sykulev; M Joo; I Vturina; T J Tsomides; H N Eisen
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

Review 2.  Ligand recognition by alpha beta T cell receptors.

Authors:  M M Davis; J J Boniface; Z Reich; D Lyons; J Hampl; B Arden; Y Chien
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

3.  Directed evolution of human T-cell receptors with picomolar affinities by phage display.

Authors:  Yi Li; Ruth Moysey; Peter E Molloy; Anne-Lise Vuidepot; Tara Mahon; Emma Baston; Steven Dunn; Nathaniel Liddy; Jansen Jacob; Bent K Jakobsen; Jonathan M Boulter
Journal:  Nat Biotechnol       Date:  2005-02-20       Impact factor: 54.908

Review 4.  Positive selection of thymocytes.

Authors:  S C Jameson; K A Hogquist; M J Bevan
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

5.  Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone.

Authors:  K Udaka; K H Wiesmüller; S Kienle; G Jung; P Walden
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

6.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.

Authors:  Rinke Bos; Linda A Sherman
Journal:  Cancer Res       Date:  2010-10-12       Impact factor: 12.701

7.  A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity.

Authors:  M D Tallquist; T J Yun; L R Pease
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

Review 8.  The role of CD4+ T cell responses in antitumor immunity.

Authors:  D M Pardoll; S L Topalian
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

Review 9.  Mechanism and biological significance of CD4-mediated cytotoxicity.

Authors:  S Hahn; R Gehri; P Erb
Journal:  Immunol Rev       Date:  1995-08       Impact factor: 12.988

10.  A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex.

Authors:  C B Williams; D L Engle; G J Kersh; J Michael White; P M Allen
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

View more
  26 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

2.  The same major histocompatibility complex polymorphism involved in control of HIV influences peptide binding in the mouse H-2Ld system.

Authors:  Samanthi Narayanan; David M Kranz
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

3.  Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Authors:  Lance M Hellman; Kendra C Foley; Nishant K Singh; Jesus A Alonso; Timothy P Riley; Jason R Devlin; Cory M Ayres; Grant L J Keller; Yuting Zhang; Craig W Vander Kooi; Michael I Nishimura; Brian M Baker
Journal:  Mol Ther       Date:  2018-12-14       Impact factor: 11.454

4.  Superantigens produced by catheter-associated Staphylococcus aureus elicit systemic inflammatory disease in the absence of bacteremia.

Authors:  Jin-Won Chung; Kerryl E Greenwood-Quaintance; Melissa J Karau; Ashenafi Tilahun; Shahryar Rostamkolaei Khaleghi; Vaidehi R Chowdhary; Chella S David; Robin Patel; Govindarajan Rajagopalan
Journal:  J Leukoc Biol       Date:  2015-05-15       Impact factor: 4.962

Review 5.  Engineered T cells for anti-cancer therapy.

Authors:  Cameron J Turtle; Michael Hudecek; Michael C Jensen; Stanley R Riddell
Journal:  Curr Opin Immunol       Date:  2012-07-18       Impact factor: 7.486

6.  2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system.

Authors:  Baoyu Liu; Shi Zhong; Karolina Malecek; Laura A Johnson; Steven A Rosenberg; Cheng Zhu; Michelle Krogsgaard
Journal:  Eur J Immunol       Date:  2013-10-20       Impact factor: 5.532

Review 7.  Designing chimeric antigen receptors to effectively and safely target tumors.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Curr Opin Immunol       Date:  2015-01-23       Impact factor: 7.486

Review 8.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.

Authors:  Jennifer D Stone; Daniel T Harris; Carolina M Soto; Adam S Chervin; David H Aggen; Edward J Roy; David M Kranz
Journal:  Cancer Immunol Immunother       Date:  2014-08-01       Impact factor: 6.968

10.  Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.

Authors:  Dongrui Wang; Brenda Aguilar; Renate Starr; Darya Alizadeh; Alfonso Brito; Aniee Sarkissian; Julie R Ostberg; Stephen J Forman; Christine E Brown
Journal:  JCI Insight       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.